*Please note that this translation is to be used solely as reference.
In case of any discrepancy between this translation and the Japanese original, the latter shall prevail.
2nd Quarter of FY 2025 Financial Results Briefing
November 20, 2024
Kazuhiro Hatano, Representative Director
Linical Co., Ltd.
TSE Standard 2183
Agenda
- Company Overview
- Financial Results for the Six Months Ended September 30, 2024
- Management Strategy
2
Corporate Profile
Company name | Linical Co.,Ltd. (TSE Standard 2183) |
Head Office | 1 -6 -1 Miyahara, Yodogawa-ku, Osaka |
Establishment | June 7, 2005 |
Representative | Kazuhiro Hatano, Representative Director |
Capital Stock | 214 million yen |
Business Description | Clinical Research & Development (CRO) business and |
Contract Medical Affairs Business | |
Number of Employees | 711 (330 in Japan and 381 overseas) * As of March 31, 2024 |
- History of establishment
April 1, 2005: Yamanouchi Pharmaceutical Co., Ltd., and Fujisawa Pharmaceutical Co., Ltd., merged to form Astellas Pharma Inc.
June 7, 2005: Linical was established centered on members with experience in drug development at Fujisawa Pharmaceuticalaimed at the ideal Contract Research Organization (CRO) business originating in Osaka.
3
Practice our business philosophy and help patients
Management Philosophy
To promote the greater wellbeing of all our stakeholders - patients, business partners, shareholders, and employees -
we strive constantly to offer professional, high-quality services to support all aspects of new drug development.
Blue: Integrity and Honesty
Red: Unending enthusiasm
Yellow: Continuing spirit of inquiry
Our corporate logo expresses our passion to pursue happiness of patients | |
through our business activities. | 4 |
The Three Businesses of Linical
- We specialize in clinical development and cover the entire process from the innovative drug development stage through to the new drug development and approval stages.
Innovative drug
development
process
Basic research | Application to | Clinical trials | Post-marketing | |
(2 to 3 years) to | New drug | surveillance and | ||
start a new | phases I to III | |||
non-clinical trials | application | clinical trials | ||
drug trial | (3 to 7 years) | |||
(3 to 5 years) | (4 to 10 years) | |||
The three
businesses of
Linical
CRO business | Contract Medical Affairs | |
From 2005 | From 2011 | |
Innovative Drug | ||
● Market analysis ● Handling of pharmaceutical affairs |
Development Business● Development strategy planning ● Partnering support
From 2016
- CRO Business: Implementing on client's behalf and supporting operations related to clinical trials conducted in the drug development stage
- Contract Medical Affairs business: We support post-marketing clinical research and marketing activities
- Innovative Drug Development Business: We provide consulting services that give total support for a wide range of pharmaceutical development activities including market analysis, the formulation of pharmaceutical affairs and development strategies, the selection of marketing partners, and the conclusion of contracts.
Targeted Therapeutic Areas
Dermatology Ophthalmology
8%5%
Endocrinology | Oncology & |
9% | Hematology |
37% |
Global
Therapeutic
Experience
Neurology | |
25% | Infectious Disease |
& Immunology | |
16% |
Since our establishment, we have focused on the therapeutic areas of
oncology, neurology and immunology, which
have a high degree of difficulty and many unmet medical needs.
6
Global CRO originating from Japan
- Our Global Network
The Americas:
United States ★
Canada ★ Preferred providers in Latin & South America
- Office/employee locations
Germany ★
UK ★
Netherlands ★
Czech ★
Spain ★
Sweden ★
Europe:
France ★ | Slovakia | |||
Italy ★ | Denmark | |||
Hungary ★ | Austria | |||
Poland ★ | Belgium | |||
Romania ★ | Switzerland | |||
Preferred providers in Portugal, Norway etc.
Asia:
Japan ★
China ★
South Korea ★
Taiwan ★
Singapore ★
India ★
Australia★
Currently has employees in about 20 countries/regions. | |
Providing services in about 30 countries including affiliated partners | 7 |
Expansion of our Global Reach
- New Jersey Office
- New office near New York to strengthen sales activities
- Established As of July 1, 2024
- Linical Australia
- First affiliate in the Southern Hemisphere
- Established As of July 9, 2024
8
Steady Growth through Overseas M&A
- Sales and Operating Income since Establishment (Billions of Yen)
Net Sales Operating Profit
(Net sales)
November 2014
10European CRO
Acquisition of Nuvisan
April 2018 | (Operating | ||
Profit) | |||
US CRO Accelovance | |||
5 | |||
Acquisition | |||
12.5 | |||
12.3 | |||
11.3 | 11.6 | ||
10.9 | 4 | ||
10.3 | |||
9.1 |
8.3
March 2013 | January 2014 | 7.7 | |||
October 2008 | First Section of | Korea CRO P-Pro | |||
the Tokyo Stock | Acquisition | ||||
5 | Mothers Listed | Exchange | |||
June 2005 | 4.9 | ||||
Establishment | 3.1 | 3.6 | 3.7 | ||
2.0 | 2.4 | 2.5 | ||
0.6 | ||||
0.1 | 1.3 | |||
COVID-19
3
2
1
0
(Fiscal year) 2006/3 2007/3 2008/3 2009/3 2010/3 2011/3 2012/3 2013/3 2014/3 2015/3 2016/3 2017/3 2018/3 2019/3 2020/3 2021/3 2022/3 2023/3 2024/3
Growth centered on overseas business through M&As in South Korea, Europe, and the | |
United States | 9 |
Sales and Employee Ratios by Region
- Net Sales: Overseas ratio 63%
Asia 11%
Japan
EU37%
23% 12.3 billion yen
（FY2024）
US
29%
- Number of employees: Overseas ratio 54%
Asia
16%
711 | Japan | |
EU | (As of the end of March | 46% |
2024) | ||
24% | * including contract | |
employees |
US
14%
Overseas ratio is more than 50% in terms of both sales and number of employees
10